Figure 2:

in vitro effects of SKI-O -703 on the proliferation, survival, and differentiation of B cells. Mouse primary B cells were labeled with CP670, and stimulated with either anti-IgM mAb, CD40L and IL-4 (A) or LPS (B) for 72 h in the presence or absence of SKI-O-703 and tofacitinib at the indicated concentrations; they were then assayed by FACS. (C and D) Mouse primary B cells were cultured as in A and B for 24 h, stained with Annexin V and 7-AAD, and assayed by FACS. Representative FACS profiles and graphs displaying mean Annexin V-positivity are shown. (E) Human primary B cells were stimulated with CpG ODN plus IL-2 (to detect IgM and IgG) or CpG ODN 2006 plus IFN-α (to detect IL-6) in the presence or absence of inhibitors. The culture supernatants were assayed by ELISA. Graphs are expressed as % positivity relative to the controls (without inhibitor). The data are representative of 2–3 independent experiments. *P < 0.05, **P < 0.01, and ***P < 0.001, compared with vehicle control by two-tailed unpaired Students t-tests.